Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest’s Board Grows, As Icahn Gains Second Director’s Seat

This article was originally published in The Pink Sheet Daily

Executive Summary

Dissident shareholder Carl Icahn will have some influence on the succession process as the New York drugmaker seeks a replacement for its retiring octogenarian CEO. Forest still needs to compensate for the loss of blockbuster antidepressant Lexapro, and could consider a sale or dramatic restructuring.


Related Content

Actavis’ Big Bet On A Diversified Hybrid Model
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Solomon To Step Aside As Forest Exec; Icahn Wins Another Victory
Forest Takes Option On Trevena’s Heart Failure Drug, And Some Equity
Many New Products For Forest, But Not Enough To Fill The Lexapro Gap
Carl Icahn’s Partial Victory In Battle For Forest: One Board Seat
Forest’s Solomon Holding Firm As Icahn Presses Second Consecutive Proxy Fight
Forest Holds Off Icahn, But Battle Likely Looms


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts